Sign In to Follow Application
View All Documents & Correspondence
View All Documents & Correspondence
Complex Comprising Ligand And Ceacam5 Antibody Fab Fragment
Abstract: [Problem] To provide a complex comprising a ligand, a spacer, and a peptide linker useful in internal diagnostics and internal radiation therapy, that uses an anti-human CEACAM5 antibody Fab fragment the binding activity of which is not weakened even by labeling with a metal, fluorescent dye, or the like. [Solution] A complex containing an anti-human CEACAM5 antibody Fab fragment, which contains a heavy chain fragment containing a heavy chain variable region comprising a specific amino acid sequence and a light chain containing a light chain variable region comprising a specific amino acid sequence, and a ligand or a complex comprising a ligand, a spacer, and a peptide linker can be used as a diagnostic composition and/or pharmaceutical composition without weakening the binding activity even by labeling by a metal, fluorescent dye, etc.
Get Free WhatsApp Updates!
Notices, Deadlines & Correspondence
Notices, Deadlines & Correspondence
Patent Information
Application #
Filing Date
03 August 2021
Publication Number
32/2021
Publication Type
INA
Invention Field
BIOTECHNOLOGY
Status
Email
patent@depenning.com
Parent Application
Applicants
ASTELLAS PHARMA INC.
5-1, Nihonbashi-Honcho 2-chome, Chuo-ku, Tokyo
1038411
Inventors
1. AKAIWA, Michinori
c/o Astellas Pharma Inc., 5-1, Nihonbashi-Honcho 2-chome, Chuo-ku, Tokyo
1038411
2. ISHIDA, Junya
c/o Astellas Pharma Inc., 5-1, Nihonbashi-Honcho 2-chome, Chuo-ku, Tokyo
1038411
3. TOYA, Hiroki
c/o Astellas Pharma Inc., 5-1, Nihonbashi-Honcho 2-chome, Chuo-ku, Tokyo
1038411
4. SHIRAISHI, Nobuyuki
c/o Astellas Pharma Inc., 5-1, Nihonbashi-Honcho 2-chome, Chuo-ku, Tokyo
1038411
5. ASANO, Toru
c/o Astellas Pharma Inc., 5-1, Nihonbashi-Honcho 2-chome, Chuo-ku, Tokyo
1038411
6. YOSHIKAWA, TOMOAKI
c/o Astellas Pharma Inc., 5-1, Nihonbashi-Honcho 2-chome, Chuo-ku, Tokyo
1038411
7. SANO, Yorikata
c/o Astellas Pharma Inc., 5-1, Nihonbashi-Honcho 2-chome, Chuo-ku, Tokyo
1038411
8. DOIHARA, Hitoshi
c/o Astellas Pharma Inc., 5-1, Nihonbashi-Honcho 2-chome, Chuo-ku, Tokyo
1038411
9. SHIRAI, Hiroki
c/o Astellas Pharma Inc., 5-1, Nihonbashi-Honcho 2-chome, Chuo-ku, Tokyo
1038411
10. HIRAYAMA, Kazunori
c/o Astellas Pharma Inc., 5-1, Nihonbashi-Honcho 2-chome, Chuo-ku, Tokyo
1038411
Specification
Documents
Application Documents
| # | Name | Date |
|---|---|---|
| 1 | 202147034949-FORM-26 [26-07-2023(online)].pdf | 2023-07-26 |
| 1 | 202147034949-TRANSLATIOIN OF PRIOIRTY DOCUMENTS ETC. [03-08-2021(online)].pdf | 2021-08-03 |
| 2 | 202147034949-Correspondence_Form1_02-12-2022.pdf | 2022-12-02 |
| 2 | 202147034949-STATEMENT OF UNDERTAKING (FORM 3) [03-08-2021(online)].pdf | 2021-08-03 |
| 3 | 202147034949-SEQUENCE LISTING(PDF) [03-08-2021(online)].pdf | 2021-08-03 |
| 3 | 202147034949-FORM 3 [28-11-2022(online)].pdf | 2022-11-28 |
| 4 | 202147034949-SEQUENCE LISTING [03-08-2021(online)].txt | 2021-08-03 |
| 4 | 202147034949-FORM 3 [26-10-2022(online)].pdf | 2022-10-26 |
| 5 | 202147034949-PROOF OF RIGHT [03-08-2021(online)].pdf | 2021-08-03 |
| 5 | 202147034949-FORM 18 [25-10-2022(online)].pdf | 2022-10-25 |
| 6 | 202147034949-PRIORITY DOCUMENTS [03-08-2021(online)].pdf | 2021-08-03 |
| 6 | 202147034949-FORM 3 [19-01-2022(online)].pdf | 2022-01-19 |
| 7 | 202147034949.pdf | 2021-10-19 |
| 7 | 202147034949-FORM 1 [03-08-2021(online)].pdf | 2021-08-03 |
| 8 | 202147034949-FORM-26 [15-09-2021(online)].pdf | 2021-09-15 |
| 8 | 202147034949-DRAWINGS [03-08-2021(online)].pdf | 2021-08-03 |
| 9 | 202147034949-CLAIMS UNDER RULE 1 (PROVISIO) OF RULE 20 [03-08-2021(online)].pdf | 2021-08-03 |
| 9 | 202147034949-DECLARATION OF INVENTORSHIP (FORM 5) [03-08-2021(online)].pdf | 2021-08-03 |
| 10 | 202147034949-COMPLETE SPECIFICATION [03-08-2021(online)].pdf | 2021-08-03 |
| 11 | 202147034949-CLAIMS UNDER RULE 1 (PROVISIO) OF RULE 20 [03-08-2021(online)].pdf | 2021-08-03 |
| 11 | 202147034949-DECLARATION OF INVENTORSHIP (FORM 5) [03-08-2021(online)].pdf | 2021-08-03 |
| 12 | 202147034949-DRAWINGS [03-08-2021(online)].pdf | 2021-08-03 |
| 12 | 202147034949-FORM-26 [15-09-2021(online)].pdf | 2021-09-15 |
| 13 | 202147034949-FORM 1 [03-08-2021(online)].pdf | 2021-08-03 |
| 13 | 202147034949.pdf | 2021-10-19 |
| 14 | 202147034949-FORM 3 [19-01-2022(online)].pdf | 2022-01-19 |
| 14 | 202147034949-PRIORITY DOCUMENTS [03-08-2021(online)].pdf | 2021-08-03 |
| 15 | 202147034949-FORM 18 [25-10-2022(online)].pdf | 2022-10-25 |
| 15 | 202147034949-PROOF OF RIGHT [03-08-2021(online)].pdf | 2021-08-03 |
| 16 | 202147034949-FORM 3 [26-10-2022(online)].pdf | 2022-10-26 |
| 16 | 202147034949-SEQUENCE LISTING [03-08-2021(online)].txt | 2021-08-03 |
| 17 | 202147034949-FORM 3 [28-11-2022(online)].pdf | 2022-11-28 |
| 17 | 202147034949-SEQUENCE LISTING(PDF) [03-08-2021(online)].pdf | 2021-08-03 |
| 18 | 202147034949-Correspondence_Form1_02-12-2022.pdf | 2022-12-02 |
| 18 | 202147034949-STATEMENT OF UNDERTAKING (FORM 3) [03-08-2021(online)].pdf | 2021-08-03 |
| 19 | 202147034949-TRANSLATIOIN OF PRIOIRTY DOCUMENTS ETC. [03-08-2021(online)].pdf | 2021-08-03 |
| 19 | 202147034949-FORM-26 [26-07-2023(online)].pdf | 2023-07-26 |